We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-20.62%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.84B
AUM Growth
-$1.19B
Cap. Flow
+$214M
Cap. Flow %
5.56%
Top 10 Hldgs %
54.93%
Holding
140
New
25
Increased
22
Reduced
18
Closed
27

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$104M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$59.7M
3
ZYME icon
Zymeworks
ZYME
+$47.4M
4
NVRO
NEVRO CORP.
NVRO
+$39.5M
5
BDTX icon
Black Diamond Therapeutics
BDTX
+$33.6M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$152M
2
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$78.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$53.8M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$37.3M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$23.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.4%
2 Financials 0.28%
3 Technology 0.27%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCPH
126
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-14,326
Closed -$892K
SWAV
127
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
– –
-30,000
Closed -$1.32M
NVTA
128
DELISTED
Invitae Corporation
NVTA
– –
-336,308
Closed -$5.42M
ARAV
129
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-32,895
Closed -$450K
ICPT
130
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-97,600
Closed -$12.1M
ZYNE
131
PUT
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-200,000
Closed -$790K
DRNA
132
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-36,496
Closed -$804K
SIC
133
DELISTED
Select Interior Concepts, Inc. Class A Common Stock
SIC
– –
-105,105
Closed -$945K
CNST
134
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-6,000
Closed -$283K
FOMX
135
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-11,203,881
Closed -$37.3M
2 3 4 5
6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2020 Portfolio in Review

As of Q1 2020, Perceptive Advisors held 140 positions worth $3.84B, down 24% from $5.03B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Perceptive Advisors deployed $214M of net new capital in Q1 2020, opening 25 new positions and adding to 22 existing holdings. Its largest new stake was Gilead Sciences: 1,500,000 shares worth $11.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Momenta Pharmaceuticals, Inc., an estimated $78.1M trimmed.

  • Perceptive Advisors's largest Q1 2020 buy was Gilead Sciences: 1,500,000 shares worth $11.2M.
  • Perceptive Advisors added most to Iovance Biotherapeutics in Q1 2020, an estimated $59.7M increase.
  • Perceptive Advisors's biggest Q1 2020 reduction was Momenta Pharmaceuticals, Inc., cutting an estimated $78.1M.
  • Perceptive Advisors fully exited Amarin Corp in Q1 2020, selling an estimated $152M.
  • Perceptive Advisors's ten largest holdings make up 55% of its $3.84B portfolio in Q1 2020.
  • Perceptive Advisors opened 25 new positions and closed 27 in Q1 2020.
  • Perceptive Advisors's portfolio value fell 24% quarter-over-quarter to $3.84B.

Based on Perceptive Advisors's 13F filing for Q1 2020, filed 15 May 2020.